Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed ovarian epithelial or primary peritoneal cancer:~Advanced disease~* Meets at least 1 of the following criteria:~  * Measurable disease;~ * Evaluable disease plus CA 125 \>= 2 times post-treatment nadir~* Treated with 1, and only 1, prior platin-containing chemotherapy regimen (e.g., paclitaxel or carboplatin-based) for ovarian epithelial or primary peritoneal cancer~* Prior treatment with the same regimen at first relapse allowed;~  * No more than 3 total chemotherapy regimens allowed provided exactly 1 has been platin-containing;~ * Must also have platin-resistant disease as defined for Group 1;~ * Rechallenge with a single regimen upon progression after a hiatus from therapy counts as a single regimen~* Group 1, meeting 1 of the following criteria:~  * Patients who relapse during or \< 6 months after completion of post-debulking chemotherapy;~ * Platinum sensitive patients in second relapse after having been treated/rechallenged with their initial regimen upon first relapse~* Group 2 (Closed to accrual as of 3/10/06):~  * Patients who relapse \>= 6 months after completion of post-debulking chemotherapy and are not retreated with the same or a different regimen~* No CNS metastases~* Performance status:~  * ECOG 0-2~* Hematopoietic:~  * Absolute neutrophil count \>= 1,500/mm3;~ * Platelet count \>= 100,000/mm3;~ * Hemoglobin \>= 10 g/dL (Note: May be supported with transfusion, epoetin alfa, or darbepoetin alfa)~* Hepatic:~  * AST =\< 2.5 times upper limit of normal (ULN);~ * Alkaline phosphatase =\< 2.5 times ULN;~ * Bilirubin =\< 1.5 times ULN~* Renal:~  * Creatinine =\< 1.5 times ULN~* Cardiovascular:~  * No cardiac arrhythmia;~ * No cardiac failure~* Not pregnant or nursing~* Negative pregnancy test~* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~* More than 3 weeks since prior radiotherapy~* Recovered from all prior therapy~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except non-melanoma skin cancer or carcinoma in situ of the cervix~* No diabetes~* No peripheral neuropathy \>= grade 2~* No baseline diarrhea (\>= 4 stools/day)~* No uncontrolled infection~* No other concurrent uncontrolled serious medical condition~* No concurrent routine colony-stimulating factors

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
- Group 2 (Type: EXPERIMENTAL): Patients receive cisplatin IV over 30 minutes and flavopiridol IV over 24 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).